EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of all-oral direct-acting antivirals on hepatocellular carcinoma in Vietnamese patients with chronic HCV genotype 1

Thong D Vo, Van Tt Bui

The Journal of Infection in Developing Countries · 2025

DOI: 10.3855/jidc.21228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Thong D Vo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Hepacivirus, Hepatitis C, Chronic. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatitis C virus (HCV) genotype 1 is a significant cause of hepatocellular carcinoma (HCC) in Vietnam. Direct-acting antivirals (DAAs) are effective in achieving sustained virologic response (SVR), potentially reducing HCC incidence. This study evaluated how DAA regimens affect HCC incidence in Vietnamese patients with chronic liver disease related to HCV genotype 1. Methodology: A retrospective cohort study was conducted with 450 HCV-1 patients treated with DAAs at the Liver Clinic, University Medical Center Ho Chi Minh City, Vietnam. Patients were followed for a median duration of 0.5 years. Treatment regimens included combinations of NS5A inhibitors with NS3/4A protease inhibitors or NS5B polymerase inhibitors. Data on demographics, baseline clinical characteristics (e.g., alpha-fetoprotein, albumin levels), and liver function were collected before initiating DAA treatment. Follow-up data, including SVR rates and HCC incidence, were assessed at the end of treatment and during the post-treatment observation period (median follow-up of 0.5 years). This approach allowed us to compare pre-treatment baseline data with post-treatment outcomes to evaluate the impact of DAA therapy on HCC risk factors and incidence.

Results

SVR was achieved in 94.8% of patients, with an HCC incidence of 1.1% at 1 year for SVR patients, versus 6.5% for non-SVR patients. Significant risk factors for HCC included hypoalbuminemia, elevated alpha-fetoprotein levels, and non-SVR status.

Conclusions

DAAs significantly reduce HCC incidence in Vietnamese patients with HCV-1; however, ongoing surveillance is essential for high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCarcinoma, HepatocellularHepacivirusHepatitis C, ChronicLiver NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedGenotypeIncidenceRetrospective StudiesSoutheast Asian PeopleSustained Virologic ResponseVietnam

Stichwörter der Autor:innen

DAAHCCHCVSVRcirrhosisgenotype 1

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.

Zitieren

APA

Vo, T. D., & Bui, V. T. (2025). Impact of all-oral direct-acting antivirals on hepatocellular carcinoma in Vietnamese patients with chronic HCV genotype 1. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.21228

Vancouver

Vo TD, Bui VT. Impact of all-oral direct-acting antivirals on hepatocellular carcinoma in Vietnamese patients with chronic HCV genotype 1. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.21228

BibTeX
@article{Vo2025,
  author = {Vo, Thong D and Bui, Van Tt},
  title = {Impact of all-oral direct-acting antivirals on hepatocellular carcinoma in Vietnamese patients with chronic HCV genotype 1},
  journal = {The Journal of Infection in Developing Countries},
  year = {2025},
  doi = {10.3855/jidc.21228}
}
Kostenlos starten →